Self-inflicted Wounds: The Impact of Operation Erva Daninha on Portugal’s Cannabis Industry
The unfolding saga of Portugal’s cannabis market has taken a dramatic turn, stemming from the Portuguese authorities’ ambitious enforcement action—Operation Erva Daninha, or “Operation Weed.” Launched in May 2025, this operation executed over 70 search warrants across Portugal and Europe, resulting in numerous arrests and the seizure of more than 7 tonnes of cannabis alongside €400,000 in cash. While the intent was to dismantle criminal organizations misusing licensed pharmaceutical firms, the repercussions on the legitimate sector have been profound.
Authorities targeted groups allegedly involved in falsifying documentation to divert products from the legal medical channel to the black market. This crackdown not only exposed regulatory weaknesses but sowed seeds of uncertainty throughout the rapidly expanding medical cannabis sector in Portugal. Multi-layered complexities have since emerged, raising questions about the future sustainability of the industry.
Despite many stakeholders welcoming the operation as a necessary step to maintain industry credibility, the fallout has been anything but supportive. Export permit approvals have skyrocketed from a manageable month-long processing time to a daunting 12 weeks. This backlog has not only stifled trade but has frustrated international partners reliant on prompt access to the Portuguese market.
Industry executives, including Michael Sassano, CEO of SOMAÍ Pharmaceuticals, caution that these delays threaten Portugal’s established position as Europe’s leading cannabis processing and export hub. The urgency for Infarmed, Portugal’s regulatory body, to streamline operations and restore confidence has never been clearer.
Arthur de Cordova, CEO of Ziel, did not mince words about the operational implications: “That blew up in Infarmed’s face.” His observation reflects the broader sentiment among businesses feeling the pressure of these delays. Adding to this sentiment, Dr. Vasco Bettencourt, Infarmed’s Director of Licensing, attempted to reassure attendees at the annual PTMC conference in Lisbon, asserting that this incident was isolated and not indicative of the industry’s health overall.
While acknowledging Bettencourt’s presence as a point of accountability, Cordova pointed out that the wider market has now been left to “pay the price,” saying, “Export permits have gone from 30 days to 70-plus days, which is a huge delay.” He painted a vivid picture of the consequences for Canadian growers sending products to Portugal for processing—essentially creating a bottleneck in the supply chain that could ripple across borders.
Knock-on Impact: A European Ripple Effect
The ramifications of Portugal’s regulatory pressure are reaching far beyond its borders, casting shadows on the entire European market. A significant concern that arises from the delays is the impending oversupply crisis in Germany. With products harvested in Canada taking an extended journey to reach European markets, delays contribute to an unsettling reality where products may be several months old upon arrival.
As Cordova explains, “Pharmacies expect at least a year of guaranteed shelf life under GMP standards. However, when products are already several months aged upon arrival, many wholesalers become hesitant to accept them.” This creates not just a supply bottleneck but amplifies the existing tensions regarding oversupply in Germany, leading to pricing pressure and growing frustrations among stakeholders.
Despite the bottleneck, the relentless flow of cannabis from the Americas is unlikely to slow down. Just as water carves new paths around an obstruction, manufacturers and exporters are beginning to seek alternative routes to market. Cordova notes that many are shifting focus to the Czech Republic and North Macedonia, regions poised to become new hubs as companies adapt to the regulatory landscape.
Crucially, this situation is driving a broader shift within the industry towards vertical integration. “Grow your own, process your own, export directly” has become the mantra for many looking to overcome the challenges posed by the current bottlenecks. This pivot could reshape the entire cannabis supply chain landscape in Europe, as businesses seek to minimize reliance on external regulatory systems that may falter under pressure.